HALOZYME THERAPEUTICS, INC. (HALO)
Biological Products, (No Diagnostic Substances)
Latest Price
$106.25
TTM P/E
31.07
Normalized P/E
36.44
Div Yield
--
Book Value
1.22
P/B Ratio
87.13
Valuation metrics
adjust assumptions →EPS: $2.56
Book value / share: $0.41
Formula: √(22.5 × EPS × BVPS)
Graham Number
$4.89
95% downside
Norm. op. income: $276M (median of 7yr)
Tax rate: 19%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$1.88
98% downside
Base FCF: $373M (median of recent 5yr)
Growth: 25%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$218.81
+106% upside
EPS: $2.56
Target P/E: 36×
Formula: EPS × P/E
P/E Fair Value
$92.16
13% downside
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13.27M | $1.04B | 11.64% | +6.0K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.35M | $418.0M | 4.69% | +80.1K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.30M | $414.0M | 4.65% | +49.8K | 2026-06-30 |
| STATE STREET CORP | 5.18M | $405.0M | 4.54% | +241.6K | 2026-06-30 |
| Invesco Ltd. | 3.18M | $248.0M | 2.79% | -834.5K | 2026-06-30 |
| MORGAN STANLEY | 2.83M | $221.0M | 2.48% | +270.3K | 2026-06-30 |
| Boston Partners | 2.77M | $216.0M | 2.43% | +89.9K | 2026-06-30 |
| BANK OF AMERICA CORP /DE/ | 2.74M | $214.0M | 2.40% | -172.5K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.52M | $197.0M | 2.21% | +14.2K | 2026-06-30 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.51M | $196.0M | 2.20% | -14.9K | 2026-06-30 |